Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.80 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.74 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25172415 | 1.00 | CRBN (0.80) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29986419 | 0.93 | CRBN (0.70) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29986108 | 0.92 | CRBN (0.69) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29986789 | 0.92 | CRBN (0.69) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24299348 | 0.90 | CRBN (0.66) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29986989 | 0.90 | CRBN (0.66) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25170816 | 0.89 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21946744 | 0.89 | CRBN (0.95) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL30139721 | 0.89 | CRBN (0.95) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL30798398 | 0.89 | CRBN (0.95) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4426286-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | Relay Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | PIK3R5, PIK3R4, PIK3R1 | CRBN 19/4885DDB1 1295/4885IKZF3 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.